Companies · Pharmaceuticals

Cane Ip Leading Holdings, Llc

SKOKIE · Pharmaceuticals

Diligence memoA one-page analyst read on Cane Ip Leading Holdings, Llc — recommendation, valuation, rhythm, risks.
$2.8M
Total raised · real
1
Rounds
Latest step-up
Top 69%
Sector rank · raised
Seed
Latest stage · inferred · Wed Dec 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Cane Ip Leading Holdings, Llc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.74× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.5 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Cane Ip Leading Holdings, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
8.5 yr record
Peak capital year was 2017 with $2.8M across 1 filings.
Market position
ahead of 32% of Pharmaceuticals peers
Capital scale is ahead of 32% of Pharmaceuticals peers; modeled value is above 56% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $2.8M across 1 filings.
  • Largest single filing was $2.8M on 2017-12-20.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Cane Ip Leading Holdings, Llc is one of 1613 Pharmaceuticals companies tracked from SKOKIE. By capital raised it ranks in the long tail (ahead of 32% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
24
Investors (latest)
2017
Year incorporated
2017-12-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2017-12-20 Raised $2.8M (real) Modeled valuation $105M (est)$2.8M$105MSeed2017

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.8M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$104.8M
Base estimate est.
$2.1M
Conservative case
$822.3M
Upside case
$13.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
8.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
8.5 yr
On record since
2017
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.8M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.6× above median
This company$2.8M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.4× above median
This company$104.8M
Sector median$76.1M

Raised more than 32% of sector peers (real $). Modeled value above 56% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 71.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)Cane Ip Leading Holdings, Llc (this company) Raised $2.8M · modeled $104.8M (est)Cane Ip Leading Holdings, Llc
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
Cane Ip Leading Holdings, Llc this companySeed$2.8M$104.8M1.74×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.8M2017-12-20$13.8M$104.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.8M2017-12-20
    • First recorded raise — entered as Seed.
    • 24 investors on this round.
Intelligence
Modeled next raise
$4.4M
Modeled next size est.range $2.9M$7.1M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
ELI DAVIS3 other2017-12
Registry & provenance

Cane Ip Leading Holdings, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1726192
SEC CIK
2017
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lotus Tissue Repair, Inc.PharmaceuticalsSeed$2.8M$104.6Msame sector · same stage
Western Oncolytics LTD.PharmaceuticalsSeed$2.8M$95.1Msame sector · same stage
iTherX Pharmaceuticals, Inc.PharmaceuticalsSeed$2.8M$105.8Msame sector · same stage
CELLECTAR, Inc.PharmaceuticalsSeed$2.7M$103.5Msame sector · same stage
JDP Therapeutics, Inc.PharmaceuticalsSeed$2.8M$76.1Msame sector · same stage
Quoin Pharmaceuticals, Inc.PharmaceuticalsSeed$2.7M$52.1Msame sector · same stage
Archer Pharmaceuticals, Inc.PharmaceuticalsSeed$2.7M$102.7Msame sector · same stage
Amplicore Inc.PharmaceuticalsSeed$2.8M$107.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cane Ip Key Holdings, LlcOther Health CareSeed$87.4M80%
Bell Pharmacy Holdings, LLCPharmaceuticalsPre-Seed$2.2M80%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M79%
Fidelis Animal Health Inc.PharmaceuticalsSeries A$6.1M79%
Supreme Pharmaceuticals Inc.PharmaceuticalsSeed$14.1M78%
CoLabs Int'l, Corp.PharmaceuticalsSeed$3.1M78%
LP Investors, LLCPharmaceuticalsSeries B$1.4B78%
Black Swan Pharmaceuticals, Inc.PharmaceuticalsSeed$39.0M78%
Frequently asked
How much funding has Cane Ip Leading Holdings, Llc raised?
Cane Ip Leading Holdings, Llc has raised approximately $2.8M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Cane Ip Leading Holdings, Llc's estimated valuation?
Provath's modeled valuation for Cane Ip Leading Holdings, Llc is approximately $104.8M (modeled range $2.1M–$822.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cane Ip Leading Holdings, Llc at?
Cane Ip Leading Holdings, Llc's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Dec 20.
What does Cane Ip Leading Holdings, Llc do and where is it based?
Cane Ip Leading Holdings, Llc operates in the Pharmaceuticals sector, based in SKOKIE.
Explore related

See where Cane Ip Leading Holdings, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cane Ip Leading Holdings, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.